Hemolytic-uremic syndrome historical perspective

	Hemolytic-uremic syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemolytic-uremic syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hemolytic-uremic syndrome historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hemolytic-uremic syndrome historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hemolytic-uremic syndrome historical perspective
CDC on Hemolytic-uremic syndrome historical perspective
Hemolytic-uremic syndrome historical perspective in the news
Blogs on Hemolytic-uremic syndrome historical perspective
Directions to Hospitals Treating Hemolytic-uremic syndrome
Risk calculators and risk factors for Hemolytic-uremic syndrome historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

HUS was first described by Gasser and colleagues in paper published in 1955^[1]^[2] .

The association between Shiga-toxin-producing bacteria and HUS was made during 35 years ago^[2].
In 1983, Karmali and colleagueswas the first to discover the association between Escherichia coli and the development of HUS^[2].
In [year], membrane cofactor protein (MCP), complement factor H (CFH) and factor I (IF) mutations were implicated in the pathogenesis of non–Shiga toxin–associated HUS^[3]

There have been several outbreaks of HUS, which are summarized below:

Shiga toxin-producing (STEC) Escherichia coli O157

In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].

The following are a few famous cases of disease name:

↑ A. Schieppati, P. Ruggenenti, R. P. Cornejo, F. Ferrario, G. Gregorini, P. Zucchelli, E. Rossi & G. Remuzzi (1992). "Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome". Journal of the American Society of Nephrology : JASN. 2 (11): 1640–1644. PMID 1610985. Unknown parameter |month= ignored (help)
↑ ^2.0 ^2.1 ^2.2 Phillip I. Tarr, Carrie A. Gordon & Wayne L. Chandler (2005). "Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome". Lancet (London, England). 365 (9464): 1073–1086. doi:10.1016/S0140-6736(05)71144-2. PMID 15781103. Unknown parameter |month= ignored (help)
↑ Jessica Caprioli, Marina Noris, Simona Brioschi, Gaia Pianetti, Federica Castelletti, Paola Bettinaglio, Caterina Mele, Elena Bresin, Linda Cassis, Sara Gamba, Francesca Porrati, Sara Bucchioni, Giuseppe Monteferrante, Celia J. Fang, M. K. Liszewski, David Kavanagh, John P. Atkinson & Giuseppe Remuzzi (2006). "Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome". Blood. 108 (4): 1267–1279. doi:10.1182/blood-2005-10-007252. PMID 16621965. Unknown parameter |month= ignored (help)